No longer trading

Acquired by BioMarin Pharmaceutical Inc.

The acquisition closed on April 27, 2026 (SEC 8-K 2.01). Its last closing price was on April 24, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from April 20, 2026. Source: SEC 8-K 2.01

FOLD

AMICUS THERAPEUTICS, INC. FOLD

NasdaqMid CapHealthcare

Final 13F Pro quality score

Final rank #1,557 of 2,819 · as of April 20, 2026

Why it scores 49Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$185.21M

Quarter to Dec 31

Net income

$1.69M

Quarter to Dec 31

Free cash flow

$15.95M

Quarter to Dec 31

Operating margin

8.6%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$11.5K total
IFP Advisors, Inc
$11.5K-2.2%
HUNTINGTON NATIONAL BANK
$140.0%
See all 2 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q4 2025
EDGAR

Net Income

Q4 2025
EDGAR

EPS (Diluted)

Q4 2025
EDGAR

Operating Margin

Q4 2025
EDGAR

ROIC

Q4 2025
EDGAR

Free Cash Flow

Q4 2025
EDGAR

Debt/Equity

Q4 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/FOLD

Earnings Per Share

13fpro.ai/company/FOLD

Loading ratio trend…

FOLD insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in FOLD

1 transaction in FOLD reported by 1 member of Congress under the STOCK Act, most recent trade Apr 10, 2023. Reported transactions, not recommendations.

All Congress stock trades →

About AMICUS THERAPEUTICS, INC. (FOLD): stock profile, AI score and financials

Acquired by BioMarin Pharmaceutical Inc.: AMICUS THERAPEUTICS, INC. (FOLD) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on April 27, 2026 (SEC 8-K 2.01). Its last closing price was on April 24, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from April 20, 2026. AMICUS THERAPEUTICS, INC. (FOLD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks FOLD using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q4 2025), AMICUS THERAPEUTICS, INC. reports quarterly revenue of $185.2M, net income of $1.7M, an operating margin of 8.6%. FOLD trades on the Nasdaq exchange and files with the SEC under CIK 1178879. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FOLD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AMICUS THERAPEUTICS, INC. directly from SEC EDGAR.

SEC EDGAR: CIK 1178879 →